Clinical Trial Update: Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update notes discontinuation of CDK4/6 inhibitors in patients with metastatic HR-positive, HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING